Meconium Aspiration Syndrome

RA'ANANA, Israel, April 3, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (NASDAQ: IINNW) (the "Company" or "Inspira"), a breakthrough medical technology company, is delighted to announce the commencement of a program to explore the applicable use of the INSPIRA™ ART100 Device for an artificial womb for neonates in need of vital respiratory support. Inspira aims to explore how this potential additional application of the INSPIRA ART100 device to provide neonates with vital respiratory support could replace the currently used mechanical ventilators. The high pressure and complications associated with mechanical ventilation can cause harsh and long-term negative effects on neonates who require respiratory life support during the early and critical stages of their neonatal development. The potential additional application targets prematurely born neonates with underdeveloped respiratory systems and neonates with life-threatening disorders such as meconium aspiration syndrome, the disorder that results in neonates experiencing difficulty in breathing as a result of meconium in the lungs, and congenital diaphragmatic hernia, where the muscle that bisects the chest from the abdomen fails to close. "Inspira is dedicated to pushing the boundaries of medical technology to save and improve lives," remarked Dagi Ben-Noon, CEO of Inspira Technologies. "This initiative marks another step in the journey towards providing safer alternatives to mechanical ventilation. Together, we are targeting to reshape the landscape of acute neonatal care." Inspira Technologies OXY B.H.N. Ltd. Inspira™ Technologies is an innovative medical technology company in the respiratory treatment arena. The Company has developed a breakthrough Augmented Respiration Technology (INSPIRA ART), designed to rebalance patient oxygen saturation levels. This technology potentially allows patients to remain awake during treatment while reducing the need for highly invasive, risky, and costly mechanical ventilation systems that require intubation and medically induced coma. The Company's products have not yet been tested or used in humans and has not been approved by any regulatory entity. For more information, please visit our corporate website:  Forward-Looking Statement Disclaimer This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses the aims of the research and development into various potential uses of the INSPIRA ART100 device and the Company's aim to reshape the landscape of acute neonatal care. These forward-looking statements and their implications are based solely on the current expectations of the Company's management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2023 filed with the U.S. Securities and Exchange Commission (the "SEC"), which is available on the SEC's website, For more details: Public Relations Manager Adi Shmueli Inspira Technologies info@inspirao2.com +972-9-9664485 Copyright © 2018-2024 Inspira Technologies OXY B.H.N. LTD., All rights reserved. Logo - SOURCE Inspira Technologies

Increasing prevalence of infectious, cardiovascular and respiratory diseases, growing adoption of ECMO in lung transplantation procedures, growth in the number of ECMO centers, increasing survival rates with ECMO and increasing strategic initiatives such as product launch or collaboration are key factors contributing to high CAGR of Extracorporeal Membrane Oxygenation (ECMO) Market during forecast period. According to the current analysis of Reports and Data, the global Extracorporeal Membrane Oxygenation (ECMO) market was valued at USD 290.2 Million in 2020 and is expected to reach USD 385.9 Million by the year 2028, at a CAGR of 3.6%. Extracorporeal membrane oxygenation is a treatment provided for COVID-19, cardiac and respiratory diseases. Increasing the prevalence of target diseases (such as COVID-19, cardiovascular diseases and respiratory diseases), technological advancements, and increasing extracorporeal membrane oxygenation centers across the globe are some of the factors driving the market growth. It is estimated that in the U.S., approximately 1,055,000 individuals will have coronary diseases, including 720,000 new and 335,000 recurrent coronary events. The number of artificial respiration via the help of the device in a developed nation such as the U.S. from the past decade is constantly on rise. With rising technological innovations improved survival rate with extracorporeal membrane oxygenation is another major factor that supports the spread of the adoption of extracorporeal membrane oxygenation in case of medical emergencies such as COVID-19 cases. In South Korea it has been observed that the inpatient with Extracorporeal membrane oxygenation therapy for respiratory failure had improved survival rate from 30.8% to 35.9%. Access Free sample PDF Copy of the Report (To Understand the Complete Structure of this Report [Summary + TOC]) @ According to the Extracorporeal Life Support Organization (ELSO), the number of hospitals offering ECMO services reached 264 in 2020, rising from 108 in 2008. Obesity often leads to poor vascular health and an increased risk of cardiovascular disease (CVD). With advent of COVID pandemic the demand for the device is expected to surge further. . However, stringent regulations in developed nations, and high associated cost of the procedure may hinder market growth in developing nations. Further key findings from the report suggest Recently, Terumo and Marker Therapeutics received FDA approval for a blood purification and oxygenation system in the treatment of COVID-19 infection. Terumo’s Spectra Optia apheresis system works with the Marker Therapeutics’ Depuro D2000 adsorption cartridges. It reduces the number of cytokines and other inflammatory blood proteins that control a cell’s immune response then filter the blood and return it to the patient. According to the FDA the proteins that are removed are typically elevated during infections, leading to severe inflammation, rapidly progressive shock, respiratory failure, organ failure and death. Various organizations and research institutes are engaged in clinical trials of the extracorporeal membrane oxygenation for cardiac and respiratory diseases. For instance, NHS ECMO completed the study of the ECMO service for adults with respiratory failure. Central Hospital, Nancy, France is engaged in studying the efficacy of Venoarterial Extracorporeal Membrane Oxygenation prior the left ventricular assist device implantation Favorable reimbursement policy such as, Medicare and Medicaid reimburse the patients going through extracorporeal membrane oxygenation procedure based on its mode of cannulation and medical indication is expected to fuel the market growth of the extracorporeal membrane oxygenation market Leading players of the market such as Getinge group recently launched its Cardiohelp System and Cardiosave Market players are focused in developing the advanced technologies in extracorporeal membrane oxygenation. For instance, MC3 Cardiopulmonary received US FDA approval for its Crescent jugular dual lumen catheter in the US for extracorporeal membrane oxygenation. In 2017, CytoSorbents Corporation launched CytoSorb Therapeutic ECMO kit in Austria. The kit combines CytoSorb blood purification cartridge with innovative tubing connector set that provide easy integration in most of the commercial ECMO systems. During 2020-2028, extracorporeal membrane oxygenation market is expected to register a CAGR of 4.8% in Asia Pacific; followed by North America and Europe, with 4.6% and 4.1% CAGR, respectively. High prevalence of severe cardiogenic shock and related diseases across the globe is the major factor driving the market during the forecast period across all regions. The venoarterial device type of extracorporeal membrane oxygenation segment dominates the field with highest market share in the year 2020. It is estimated to grow at a CAGR of 4.4% during the forecast period to reach USD 156.61 million by 2028 Based on end use segment, pediatric is expected to account for the CAGR 3.6% of the global extracorporeal membrane oxygenation market, as growing incidences of birth defect and premature birth across the world and raising public awareness about the technologically advanced respiratory support Asia Pacific is expected to grow at the highest rate. Developing nations such China, and India are likely to witness high growth due to high prevalence of cardiac and pulmonary diseases, increased healthcare expenditure and growing R&D investment High cost of the the procedure and lack of skilled personnel are the key factors likely to hamper growth of the extracorporeal membrane oxygenation market The ongoing pandemic is significantly changing the dynamics of the pharma and healthcare sector. Various countries are facing challenges such as shortage of medicines, vaccines, healthcare devices in hospitals. This is expected to open lucrative growth opportunities for market players in the coming years. For Inquiry Before Buying @ Competitive Landscape: The global market comprises various market players operating at regional and global levels. These key players are adopting various strategies such as R&D investments, license agreements, partnerships, merger and acquisitions, collaborations, and joint ventures to gain robust footing in the market. Top Companies Profiled in the Report: Getinge Group (Sweden), Medtronic plc (Ireland), LivaNova PLC (U.K.), XENIOS AG (Germany), Terumo Corporation (Japan), MicroPort Scientific Corporation (China), NIPRO Corporation (Japan), OriGen Biomedical, Inc. (U.S.), ALung Technologies, Inc. (Germany), and EUROSETS S.r.l. (Italy). Browse Full Report Description with Research Methodology, Table of Content and Infographics @ Extracorporeal Membrane Oxygenation Market Segmentation: Type Outlook (Revenue, USD Million; 2020-2028) Venovenous ECMO Venoarterial ECMO Arteriovenous ECMO Component Outlook (Revenue, USD Million; 2020-2028) Pumps Cannula Oxygenators Gas Blender Heat Exchanger Pressure Monitor Bladder Reservoir Controller Gas Cylinder Others Application Outlook (Revenue, USD Million; 2020-2028) Congenital Diaphragmatic Hernia (CDH) Birth Defects of the Heart Meconium Aspiration Syndrome (MAS) Severe Pneumonia Severe Air Leak Problems Severe High Blood Pressure in the Arteries of the Lungs (PPHN) Others Regional Outlook: North America (U.S., Canada, Mexico) Europe (Germany, U.K., Italy, France, BENELUX, Rest of Europe) Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific) Latin America (Brazil, Rest of LATAM) Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa) Ask for Customize Research Report @ This study aims to define market sizes and forecast the values for different segments and countries in the coming eight years. The study aims to include qualitative and quantitative perspectives about the industry within the regions and countries covered in the report. The report also outlines the significant factors, such as driving factors and challenges, that will determine the market’s future growth. Explore More Industry Research by Reports and Data: Point of Care Molecular Diagnostics Market Analysis, By Product And Services (Assay Kits, Software, And Services), By Technology (PCR, IN-Situ Hybridization), By Application (Oncology), By End Use (Decentralized Labs, Hospitals), And Forecasts To 2028 - Download PDF Brochure Palliative Care Market By Care Type (Hospital Inpatient Care, Private Resident Care, Hospice Resident Care, Nursery and Residential Facility Care, Others), By Application (Cancer, Chronic obstructive pulmonary disease (COPD), Cardiac diseases, Alzheimer’s, Parkinson’s, Kidney failure, Amyotrophic Lateral Sclerosis (ALS), Others), By End-Use (Hospital, Palliative Care centers, Home Care Settings, Long-term Care Centers and Rehabilitation Centers) And By Region, Forecast To 2028 - Download PDF Brochure Pelvic Organ Prolapse Repair Market Size, Share And Industry Analysis By Treatment Type (Surgical, Non-surgical), By Application (Cystocele, Uterine Prolapse, Rectocele, Enterocele, Others), By End-user (Hospital, Ambulatory Surgical Centers, Clinic, Other) And Region, Segment Forecasts To 2028 - Download PDF Brochure Peripheral Intravenous Catheters Market By Type (Short Peripheral IV Catheter and Integrated/Closed Peripheral IV Catheter), By Technology, By Application (Renal Disease, Oncology, Pediatric Disease, Gastroenterology, Infectious Disease), And By End Users, Forecast To 2020-2028 - Download PDF Brochure About Reports and Data Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors. Contact Us: John W Head of Business Development Reports And Data | Web: Direct Line: +1-212-710-1370 E-mail: sales@reportsanddata.com LinkedIn | Twitter | Blogs Read the innovative blog at Check out our upcoming research report at For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update:

PUNE, India, July 07, 2021 (GLOBE NEWSWIRE) -- The Global Artificial Lungs Market Share, Trends, Analysis and Forecasts, 2020-2030 provides insights on key developments, business strategies, research & development activities, supply chain analysis, competitive landscape, and market composition analysis. The artificial lung (AL) is a prosthetic gadget that transfers oxygen to the blood and eliminates carbon dioxide from the blood. Artificial Lungs is expected to replace a fair share of the functions that the natural lung performs in human body in near future. Artificial lung gadgets for quite a long time have been utilized in babies and youngsters with lung disorders namely, pneumonia, meconium inhalation condition and various other respiratory malfunctions. Along with utilizing conventional procedures (upper bar), artificial lung (AL) support is initiated when the other treatment options, including mechanical ventilation (MV), are of no help in improving the patient's condition. Respiratory assistance gadgets like artificial lungs could at last get practically importance equivalent to ventricular aiding gadgets. Breethe, Inc. (Baltimore-based clinical gadget organization) acquired restrictive rights of College of Maryland. Breethe, Inc. (Baltimore-based clinical gadget organization) accesses the protected institution of the college involved in the furtherance of a portable, easy to carry, wearable blood siphon oxygenator that will help in betterment of patient encountering cardiopulmonary collapse and respiratory failure. View the Entire report with Table of Contents: Primary recipients of Artificial Lungs Patients suffering from End-stage lungs illness, specifically chronic obstructive pulmonary infections (COPD) patients, serious pulmonary hypertension (PAH), Intense respiratory pain disorder (ARDS) are prescribed Artificial lungs. Advantages of artificial lungs over other devices Large area diffusion contraptions (micro fluidic lungs) attached with 3D geographical proved to be a progressive leap in the Artificial lungs field and will beat a significant impediment to the clinical application of artificial lungs. Artificial lungs have improved gas movement performance contrasted with current gadgets to allow respiratory help of patients suffering from advanced stages of respiratory illnesses. Another advantage of artificial lungs is expanded biocompatibility to establish gadget lifespan, which lends a helping hand in granting long-term treatment, and progress in patient wellbeing. Also, expanded convenience to allow mobile or portable treatments and bettered patient personal satisfaction is helping artificial lungs in its growth worldwide. Access Sample Pages of this Report: Growth driving factors of Artificial Lungs Market Advancements and research carried out extensively in artificial lung technology innovation, including bettered shapes, improved tubing, and ambulatory aid methods, make it progressively conceivable to help select patients effectively, allowing them to endure the selection for a reasonable donor lung, and, significantly, to accomplish a fruitful post-transplant result. Recently, enhancements in persistent selection, a superior understanding and further comprehension of ventilator-related lung injuries, and upgrades in artificial lung gadget transformations have made it conceivable to effectively connect patients to healing or to lung transplantation. Rising frequency of respiratory issue and developing issues with lungs has increased evolution of the worldwide artificial lung market. Additionally, it is likewise utilized as an oxygenator while doing cardiovascular medical procedures. Owing to this factor, various organizations are putting forth attempts in creating functional user-friendly oxygenators that are thriving competition in this market. Analysts and researchers are putting forth diligent attempts in creating and improving artificial lungs, with which it very well may be utilized at bigger scope and with greater comfort. Major players in the market are additionally putting forth comparative attempts that will profit the development in the worldwide artificial lung market. The leading market segments of Global Artificial Lungs Market North America is projected to lead the worldwide artificial lung market during 2020-2030 owing to coronavirus outbreak. Presence of key regional players, expanding endeavors made in clinical innovative work, and high venture made in creating and improving artificial lung has made this region lead the worldwide artificial lung market. Rising attentiveness among people has additionally altered development positively in North America artificial lung market. The rising frequencies of cardiovascular illnesses are required to drive the market over the speculated time frame. Related report: Global Entecavir Market: Global Genomics Market: Global Fabry Disease Treatment Market: As indicated by the American School of Cardiology, cardiovascular illness represented 800,000 mortalities in the US in 2017 alone. Along this very same line of reference, among Americans, a normal of one person dies from cardiovascular infection every 40 seconds. Coronary illness represents most of CVD death counts, trailed by stroke and cardiovascular breakdown. The key players of the Global Artificial Lungs Market are: ALung Technologies, Breethe, Haemair, Lung Biotechnology PBC, McGowan Institute for Regenerative Medicine, MedArray, Michigan Critical Care Consultants, Miromatrix Medical, The Charles Stark Draper Laboratory, Xenios. Buy This Report: Global Artificial Lungs Market Key Segments: Product Type Application Type By Region insightSLICE is a market intelligence and strategy consulting company. The company provides tailor-made and off the shelf market research studies. The prime focus of the company is on strategy consulting to provide end-to-end solutions. For more details, please contact our research and consulting team at info@insightslice.com . Contact Us: Alex, insightSLICE Phone (USA): +1 707 736 6633 Email address: alex@insightslice.com Web: